ADVERTISEMENT
Momelotinib Demonstrates Consistent Long-Term Safety in Patients With Myelofibrosis
Pooled Data From 3 Randomized-Controlled Phase 3 Trials: SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM
Pooled Data From 3 Randomized-Controlled Phase 3 Trials: SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM
Srdan Verstovsek, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, discusses the long-term safety of momelotinib in patients with high- and intermediate-risk myelofibrosis.
Per the data evaluated in 3 randomized-controlled trials (SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM), momelotinib demonstrated a consistent safety profile without unexpected long-term or cumulative toxicity. These results were presented at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.
Source:
Verstovsek S, Mesa R, Gupta V et al. Momelotinib (MMB) Long-Term Safety: Pooled Data from 3 Phase 3 Randomized-Controlled Trials (RCTs). Presented at the ASH Annual Meeting & Exposition; December 10-13, 2022; New Orleans, LA, and virtual. Abstract 4348.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement